A Randomized, Double-Blind, Controlled Trial to Assess the Efficacy of a Fortetropin Supplement in Improving Symptoms of Osteoarthritis

This is a hybrid, double‐blind, randomized, placebo‐controlled clinical trial that will last 12 weeks. Participants will be randomized into either the intervention product or control group and will consume the test product or control daily. Participants will complete study‐specific and validated questionnaires at Baseline, Week 6, and Week 12, as well as blood biomarker testing for a lipid panel and high‐sensitivity C‐reactive protein (hs‐CRP) at Baseline and Week 12. Osteoarthritis‐like symptoms, such as joint pain, inflammation, and reduced mobility will be evaluated at baseline and at each check‐in. Likert scale responses will be examined from baseline to each check‐in. Participant responses on product feedback will be presented as % scores. Two validated questionnaires, Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the Numeric Pain Rating Scale (NPRS) will also be completed at the questionnaire time points. A full lipid panel and hs‐CRP measurement will be completed via in‐person blood draws.